BIOSECURE Act Excluded from Defense Bill, Easing Pressure on Chinese Biotech
The BIOSECURE Act, which aims to restrict U.S. pharmaceutical companies from using Chinese contract manufacturers like WuXi AppTec and WuXi Biologics, was excluded from a crucial defense budget bill. This legislation, supported by both parties, seeks to reduce reliance on China in the drug supply chain and maintain U.S. dominance in biotechnology. However, the exclusion from the defense bill represents a significant setback for the act.
